Article
Immunology
Caterina Francesca Bagella, Davide G. Corda, Pietro Zara, Antonio Emanuele Elia, Elisa Ruiu, Elia Sechi, Paolo Solla
Summary: This study reported cases of Guillain-Barre syndrome after COVID-19 vaccination, highlighting the need for close monitoring in these patients after the acute phase to exclude chronic evolution of the disease.
Article
Clinical Neurology
Umair J. Chaudhary, Yusuf A. Rajabally
Summary: Underdiagnosis of CIDP is common and can result in significant delays in diagnosis and treatment initiation. Lack of comprehensive attention to typical electroclinical features of CIDP and its diagnostic criteria at the time of initial evaluation contributes to underdiagnoses.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Huajian Zhao, Yiming Zheng, Lingchao Meng, Meng Yu, Wei Zhang, He Lv, Zhaoxia Wang, Hongjun Hao, Yun Yuan
Summary: In patients with CIDP, involvement of cranial nerves is not common, while facial palsy and hypoglossal nerve involvement may occur. Inverted Beevor's sign was observed in a patient with CIDP.
Article
Clinical Neurology
Susanna B. Park, Tiffany Li, Matthew C. Kiernan, Nidhi Garg, Ian Wilson, Richard White, Michael Boggild, Andrew McNabb, Matthew Lee-Archer, Bruce Taylor
Summary: This study investigated the prevalence of CIDP and MMN in Australia and found that the prevalence of CIDP was approximately 5.00 per 100,000 people and the prevalence of MMN was approximately 1.33 per 100,000 people. These findings are important for future resource planning and treatment monitoring.
Letter
Clinical Neurology
Adaja E. Baars, Pieter A. A. Van Doorn, Bart C. C. Jacobs, Krista Kuitwaard
Summary: We appreciate Dr. Harth's comment on our recent study on the risk of GBS recurrences and exacerbations of CIDP or multifocal motor neuropathy after SARS-CoV-2 vaccination. However, we regret that our colleague experienced brachial plexopathy and dysautonomia after a third COVID-19 vaccination, and vaccination cannot be ruled out as a potential cause without other antecedent events.
Review
Clinical Neurology
Felix Kohle, Satoshi Kuwabara, Helmar Christoph Lehmann
Summary: Pregnancy can trigger typical CIDP in some women, and women with CIDP have a higher risk of relapse during pregnancy. The onset or relapse of CIDP during pregnancy is a rare but challenging constellation for physicians.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Review
Biochemistry & Molecular Biology
Edyta Dziadkowiak, Marta Waliszewska-Prosol, Marta Nowakowska-Kotas, Slawomir Budrewicz, Zofia Koszewicz, Magdalena Koszewicz
Summary: This article reviews the pathophysiology of different clinical phenotypes of chronic inflammatory demyelinating polyneuropathy (CIDP), as well as ongoing research in this field, with reference to key points of immune-mediated processes involved in the background of CIDP. In recent years, there has been rapid progress in understanding the mechanism and treatment response of CIDP.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Ivan Kmezic, Kristin Samuelsson, Anja Finn, Zane Upate, Kaj Blennow, Henrik Zetterberg, Rayomand Press
Summary: This study investigates the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies. The results show higher levels of neurofilament light chain (NfL) and total tau (T-tau) in cerebrospinal fluid (CSF) and plasma of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and paraproteinemia-related demyelinating polyneuropathy (PDN). NfL levels in CSF and plasma correlate with disability scores in GBS patients. T-tau in plasma is a novel biomarker that could be used for the diagnostic assessment of acute and chronic inflammatory polyneuropathies.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Martin K. R. Svacina, Man Mohan Mehndiratta, Christian A. Vedeler, Yogesh Sharma, Ilja Bobylev, Alina Sprenger, Gina Remke, Hauke Wustenberg, Ines Klein, Abhijeet Joshi, Helmar C. Lehmann
Summary: The multicentre study compared clinical management of CIDP in Germany, India, and Norway, revealing differences in diagnostic and therapeutic procedures, with Indian patients being the most severely affected with fewer therapeutic approaches. This exploratory study highlights an unaddressed issue in CIDP management that should be further investigated to optimize the standard of care for CIDP worldwide.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Pietro Emiliano Doneddu, Chiara Briani, Dario Cocito, Fiore Manganelli, Gian Maria Fabrizi, Sabrina Mata, Anna Mazzeo, Raffaella Fazio, Luana Benedetti, Marco Luigetti, Maurizio Inghilleri, Elisa Ruiu, Gabriele Siciliano, Giuseppe Cosentino, Girolama Alessandra Marfia, Marinella Carpo, Massimiliano Filosto, Giovanni Antonini, Francesca Notturno, Stefano Sotgiu, Laura Cucurachi, Claudia Dell'Aquila, Elisa Bianchi, Tiziana Rosso, Andrea Giordano, Marco Fernandes, Marta Campagnolo, Erdita Peci, Emanuele Spina, Matteo Tagliapietra, Martina Sperti, Luca Gentile, Camilla Strano, Francesco Germano, Marina Romozzi, Federica Moret, Ignazio Roberto Zarbo, Divina Valeria Viola, Elisa Vegezzi, Giorgia Mataluni, Stefano Cotti-Piccinelli, Luca Leonardi, Alessandra Carta, Eduardo Nobile-Orazio
Summary: This study evaluated the risk of relapse and the safety of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies. The results showed that mild and transient relapses occurred in 5% of patients after vaccination, with no increase in the specific risk of relapse associated with the type of vaccine or diagnosis.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Medicine, General & Internal
Dario Cocito, Erdita Peci, Maria Claudia Torrieri, Marinella Clerico
Summary: The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg) in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but better tolerated and easier to administer. It is also more convenient and cost-effective, allowing for flexible treatment scheduling at home and improving patients' overall quality of life.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Ayse Nur Ozdag Acarli, Gokcen Unverengil, Nermin Gorkem Sirin, Arman Cakar, Hacer Durmus, Yesim Parman
Summary: This study examined small-fiber involvement in patients with CIDP and CIDP variants, finding significant reductions in intraepidermal nerve fiber densities compared to healthy controls. The reductions were particularly pronounced in the distal leg and were associated with clinical outcome measures. In clinically unstable CIDP patients, the reductions in nerve fiber densities were more severe.
Article
Cell Biology
Ivo Bozovic, Vladimir Perovic, Ivana Basta, Stojan Peric, Zorica Stevic, Dusan Popadic, Irena Vukovic, Aleksandar Stojanov, Emina Milosevic
Summary: The role of innate and adaptive immune responses in CIDP pathogenesis is mediated by cytokine production. Single-nucleotide polymorphisms (SNPs) in cytokine genes may affect the pathogenesis of autoimmune diseases. However, the impact of cytokine gene SNPs in CIDP patients has not been assessed yet.
Article
Clinical Neurology
Jeffrey A. Allen, Richard A. Lewis
Summary: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic immune-mediated peripheral form of polyneuropathy. Diagnosis of CIDP can be challenging, but clinicians can utilize diagnostic criteria and assessment of treatment response to aid in diagnosis and treatment.
Article
Behavioral Sciences
Karissa L. Gable, Stojan Peric, Michael W. Lutz, Ivo Bozovic, Milutin Petrovic, Aleksandar Stojanov, Ivana Basta, Jeffrey A. Allen
Summary: This study aimed to evaluate changes in fatigue in CIDP patients over one year and correlate them with changes in disability and quality of life. The results showed that worsening fatigue was associated with increased disability and worse quality of life. Additionally, fatigue was not specific to CIDP but common in many chronic medical conditions and with the use of sedating medications.
BRAIN AND BEHAVIOR
(2022)
Article
Immunology
Moritz Z. Kayser, Benjamin Seeliger, Christina Valtin, Jan Fuge, Stefan Ziesing, Tobias Welte, Mathias W. Pletz, Patrick Chhatwal, Jens Gottlieb
Summary: The study showed that BFPPp offered faster test results compared to conventional tests, which led to quicker clinical decisions. BFPPp demonstrated high accuracy in diagnosing viral LRTI, non-viral LRTI, and combined viral and non-viral LRTI. Additionally, preliminary therapies based on BFPPp results were upheld in 90% of cases.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Rheumatology
Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, Vincent Cottin, Franco Franceschini, Stefano Del Giacco, Franco Schiavon, Thomas Neumann, Giuseppe Lopalco, Pavel Novikov, Chiara Baldini, Carlo Lombardi, Alvise Berti, Federico Alberici, Marco Folci, Simone Negrini, Renato Alberto Sinico, Luca Quartuccio, Claudio Lunardi, Paola Parronchi, Frank Moosig, Georgina Espigol-Frigole, Jan Schroeder, Anna Luise Kernder, Sara Monti, Ettore Silvagni, Claudia Crimi, Francesco Cinetto, Paolo Fraticelli, Dario Roccatello, Angelo Vacca, Aladdin J. Mohammad, Bernhard Hellmich, Maxime Samson, Elena Bargagli, Jan Willem Cohen Tervaert, Camillo Ribi, Davide Fiori, Federica Bello, Filippo Fagni, Luca Moroni, Giuseppe Alvise Ramirez, Mouhamad Nasser, Chiara Marvisi, Paola Toniati, Davide Firinu, Roberto Padoan, Allyson Egan, Benjamin Seeliger, Florenzo Iannone, Carlo Salvarani, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi
Summary: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks proved effective in treating EGPA, with no significant difference between the two doses. Complete response rates reached 30.4% at 12 months and 35.7% at 24 months, with some patients experiencing exacerbations in asthma and ENT.
ARTHRITIS & RHEUMATOLOGY
(2022)
Letter
Critical Care Medicine
Benjamin Seeliger, Pedro David Wendel-Garcia, Klaus Stahl, Christian Bode, Sascha David
INTENSIVE CARE MEDICINE
(2022)
Article
Clinical Neurology
Anna Lena Fisse, Jeremias Motte, Thomas Grueter, Felix Kohle, Cornelius Kronlage, Jan-Hendrik Stahl, Natalie Winter, Tabea Seeliger, Stefan Gingele, Frauke Stascheit, Benjamin Hotter, Juliane Klehmet, Karsten Kummer, Elena K. Enax-Krumova, Dietrich Sturm, Thomas Skripuletz, Jens Schmidt, Min-Suk Yoon, Kalliopi Pitarokoili, Helmar C. Lehmann, Alexander Grimm
Summary: This study investigates the current care of patients with immune-mediated polyneuropathies in specialized centers in Germany and provides important epidemiological insights. The findings suggest that the development of specific treatment and follow-up recommendations is necessary to ensure a uniform standard of patient care.
Article
Clinical Neurology
Tabea Seeliger, Henrike Neelke Dreyer, Janna Margaretha Siemer, Lena Boenig, Stefan Gingele, Maike Franziska Dohrn, Nils Prenzler, Diana Ernst, Torsten Witte, Thomas Skripuletz
Summary: Sjogren's syndrome is a potentially treatable cause of Small Fiber Neuropathy (SFN). This study found no significant differences in symptoms and cerebrospinal fluid parameters between SFN patients with and without Sjogren's syndrome. However, SFN patients with Sjogren's syndrome had lower intraepidermal nerve fiber densities, suggesting a different pathomechanism.
JOURNAL OF NEUROLOGY
(2023)
Review
Endocrinology & Metabolism
Alireza Soleimani, Sajjad Ghane Ezabadi, Nora Moehn, Zahra Moghimi Esfandabadi, Zahra Khosravizadeh, Thomas Skripuletz, Maryam Azimzadeh
Summary: Hormonal imbalance is a significant factor in the severity of multiple sclerosis (MS). Hormone therapy has shown potential in regulating the immune system and protecting nerves in experimental studies. Thyroid, melatonin, and sex hormones have been found to improve neurological impairment by regulating the immune system, providing neuroprotection, and reducing oxidative stress. Understanding hormone therapy can lead to the identification of new molecular/cellular pathways in MS.
METABOLIC BRAIN DISEASE
(2023)
Review
Clinical Neurology
Franz Felix Konen, Philipp Schwenkenbecher, Mike P. Wattjes, Thomas Skripuletz
Summary: This article reviewed and analyzed published studies comparing the use of the 2017 and 2010 McDonald criteria in terms of diagnostic performance. The results showed that the 2017 McDonald criteria diagnosed more patients with multiple sclerosis (MS) and enabled earlier diagnosis compared to the 2010 revision. The improvement was achieved through adjustments in imaging criteria and the introduction of oligoclonal bands as a diagnostic criterion.
Article
Cardiac & Cardiovascular Systems
Clara L. L. Zippel, Sonja Beider, Emelie Kramer, Franz F. F. Konen, Tabea Seeliger, Thomas Skripuletz, Stefanie Hirsch, Alexandra Jablonka, Torsten Witte, Kristina Sonnenschein, Diana Ernst
Summary: This study investigated specific risk factors for cardiovascular disease in patients with primary Sjogren's syndrome (pSS) and found that hypertension, hypercholesterolemia, diabetes, vasculitis, and Raynaud's phenomenon were associated with cardiovascular disease in pSS patients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Clinical Neurology
Tabea Seeliger, Emelie Kramer, Franz Felix Konen, Nadine Zehrfeld, Sonja Beider, Nils Kristian Prenzler, Vega Goedecke, Torsten Witte, Thomas Skripuletz, Diana Ernst
Summary: By systematically evaluating neurological manifestations of primary Sjogren's syndrome, we found that patients with neurological involvement had different clinical characteristics compared to those without neurological involvement. Male sex, older age, hospitalization at first presentation, lower IgG levels, and higher eosinophil values were identified as independent predictors of neurological involvement in Sjogren's syndrome. These findings suggest that neurological involvement in Sjogren's syndrome has been underestimated, and intensified screening for neurologic involvement should be included in the diagnostic algorithm.
JOURNAL OF NEUROLOGY
(2023)
Article
Oncology
Nora Moehn, Susann Mahjoub, Laura Duzzi, Emily Narten, Lea Grote-Levi, Gudrun Koerner, Tabea Seeliger, Gernot Beutel, Benjamin-Alexander Bollmann, Thomas Wirth, Andre Huss, Hayrettin Tumani, Imke Grimmelmann, Ralf Gutzmer, Philipp Ivanyi, Thomas Skripuletz
Summary: Immune checkpoint inhibitors have shown great potential in treating cancer, but the occurrence of immune-related adverse events, particularly neurological events, is a concern. Currently, there are no reliable biomarkers to diagnose and predict these events.
Article
Medicine, General & Internal
Konrad Peukert, Andrea Sauer, Benjamin Seeliger, Caroline Feuerborn, Mario Fox, Susanne Schulz, Lennart Wild, Valeri Borger, Patrick Schuss, Matthias Schneider, Erdem Gueresir, Mark Coburn, Christian Putensen, Christoph Wilhelm, Christian Bode
Summary: Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure characterized by immune imbalance and damage to the alveolar epithelial and endothelial cells. Pulmonary superinfections occur in up to 40% of ARDS patients, leading to poor prognosis and increased mortality. This study aimed to identify a distinct pattern of pulmonary injury and pro-inflammatory response in ARDS patients who develop pulmonary superinfections. The analysis of serum and BALF samples revealed significantly increased levels of the cytokine IL-18 and the epithelial damage markers SP-D and sRAGE in ARDS patients with pulmonary superinfections. These findings suggest inflammasome activation and alveolar epithelial injury as potential biomarkers for identifying high-risk patients and developing targeted preventive strategies and personalized treatments.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Clinical Neurology
Antonios Bayas, Monika Christ, Simon Faissner, Juliane Klehmet, Refik Pul, Thomas Skripuletz, Sven G. Meuth, SPMS Working Group
Summary: Although the understanding of SPMS is evolving, early detection of relapse-independent progression remains difficult. The term RMS includes RRMS and SPMS with relapses, and disease-modifying therapies approved for RMS or active SPMS are used. However, there are differences in efficacy and safety evidence between drugs approved for RMS and SPMS. Clinical trials have shown that siponimod and interferon-beta 1b s.c. have significant reductions in disability progression in SPMS populations, but data on other drugs approved for RMS are limited to small subgroups and the potential to reduce relapse-independent progression is unclear.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Meeting Abstract
Clinical Neurology
Kelly Gwathmey, Gregory Sahagian, Yessar Hussain, Marc Feinberg, Ali Habib, Thomas Skripuletz, Tobias Ruck, Edward Brauer, Deborah Gelinas, Sihui Zhao, Anna Bogatyreva, Renato Mantegazza
Meeting Abstract
Clinical Neurology
Kelly Gwathmey, Gregory Sahagian, Yessar Hussain, Marc Feinberg, Ali Habib, Thomas Skripuletz, Tobias Ruck, Michael Rivner, Fang Sun, Edward Brauer, Deborah Gelinas, Li Liu, Jana Podhorna, Renato Mantegazza
Article
Clinical Neurology
Majid Esmaeilzadeh, Mete Dadak, Oday Atallah, Nora Mohn, Thomas Skripuletz, Christian Hartmann, Rozbeh Banan, Joachim K. Krauss
Summary: IgG4-related hypertrophic pachymeningitis is a rare disease with diverse clinical manifestations, challenging diagnosis and treatment.
ACTA NEUROCHIRURGICA
(2022)